C1orf167 Inhibitors
C1orf167 inhibitors encompass a diverse array of chemical compounds that attenuate the protein's activity. Staurosporine, a broad-spectrum kinase inhibitor, and chelerythrine, a specific inhibitor ofProtein Kinase C, diminish the functional activity of C1orf167 by interfering with kinase-related signaling, which is crucial for phosphorylation events that C1orf167 may depend on. If C1orf167's functionality is intertwined with the phosphoinositide 3-kinase (PI3K)/AKT pathway, the use of LY 294002 and Wortmannin, both PI3K inhibitors, would result in a decreased AKT phosphorylation, thereby indirectly reducing C1orf167's activity. Similarly, compounds like PD 98059, U0126, and SB 203580 inhibit different nodes within the MAPK signaling cascade; PD 98059 and U0126 target MEK, while SB 203580 specifically inhibits p38 MAPK. If C1orf167 functions within this cascade, these inhibitors would disrupt the pathway, leading to a decrease in C1orf167 activity. Rapamycin, targeting mTOR signaling, would also downregulate C1orf167 if it is reliant on mTORC1's role in protein synthesis modulation.
Moreover, Sunitinib's role as a receptor tyrosine kinase (RTK) inhibitor suggests that if C1orf167's activity is connected to RTK signaling, blocking these kinases would result in suppressed C1orf167 function. Bortezomib operates through proteasome inhibition, which could decrease C1orf167's activity by altering the degradation rates of proteins that regulate C1orf167's function or by maintaining proteins that act as C1orf167 suppressors. Triciribine, targeting AKT, would impede any downstream signaling related to C1orf167, assuming there is a regulatory relationship. Lastly, SP600125's inhibition of c-Jun N-terminal kinase (JNK) might lower C1orf167 activity by reducing AP-1 transcription factor activity, which could be essential for C1orf167's expression or function. Collectively, these inhibitors work through distinct but interrelated mechanisms to diminish the functional activity of C1orf167 by impacting signaling pathways and molecular processes that are potentially pivotal for its role in cellular physiology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent non-selective kinase inhibitor that likely inhibits the kinase activity associated with C1orf167. If C1orf167 has kinase activity or interacts with kinases, staurosporine would diminish its functional activity by preventing ATP binding and subsequent phosphorylation events. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of phosphoinositide 3-kinases (PI3Ks), which may indirectly reduce C1orf167's activity if it is part of or regulated by the PI3K/AKT pathway. Inhibition of PI3Ks leads to a decrease in AKT phosphorylation, diminishing downstream signaling that could be crucial for the functionality of C1orf167. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of mitogen-activated protein kinase kinase (MEK), which may diminish C1orf167's activity if it is involved in the ERK/MAPK pathway. By blocking MEK, PD 98059 prevents the activation of ERK, which could be necessary for C1orf167's functional role in the cell. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can reduce the activity of C1orf167 if it is involved in mTOR signaling. Rapamycin binds to FKBP12 and the complex inhibits mTORC1, leading to diminished protein synthesis and potentially reducing C1orf167 activity if it requires mTORC1 signaling for its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A specific inhibitor of p38 MAPK, which could indirectly diminish the activity of C1orf167 if it is involved in stress response signaling. By inhibiting p38 MAPK activation, SB 203580 would decrease the cellular responses to stress where C1orf167 might play a role. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor that can diminish C1orf167 activity by preventing AKT phosphorylation if C1orf167 is part of the PI3K/AKT pathway. Wortmannin is an irreversible inhibitor, leading to sustained inhibition of the pathway. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
A specific AKT inhibitor that could diminish the activity of C1orf167 if it functions downstream of or is regulated by AKT signaling. By inhibiting AKT, triciribine reduces the phosphorylation and activation of downstream targets that could include C1orf167. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which may diminish C1orf167 activity if C1orf167 is involved in AP-1 transcription factor regulation. SP600125 inhibits JNKs, thus potentially reducing the transcriptional activity of AP-1 and the expression of genes where C1orf167 could be a regulatory factor. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that could diminish the functional activity of C1orf167 by inhibiting the degradation of regulatory proteins that control C1orf167 function or by stabilizing proteins that suppress C1orf167 activity. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $88.00 $311.00 | 17 | |
A potent inhibitor of Protein Kinase C (PKC) that could diminish the activity of C1orf167 if C1orf167 is regulated by or associated with PKC-dependent signaling pathways. | ||||||